Compare Citius Pharmaceuticals Inc (CTXR) vs Expensify Inc (EXFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Expensify Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Expensify Inc trades at $2.42 (market cap $208.82M). The key difference: Expensify Inc is far larger — about 15.3× Citius Pharmaceuticals Inc's market cap, and Expensify Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Expensify Inc for 41 Days on average.
| CTXR | EXFY | |
|---|---|---|
Market Cap | $13.62M | $208.82M |
Volume | 132,438 | 456,102 |
Sector | Health | Technology |
52-Week High | $1.82 | $2.72 |
52-Week Low | $0.48 | $0.75 |
Typical Hold Time | 16 Days | 41 Days |
Enterprise Value | $3.79M | $148.44M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
Expensify (EXFY) trades at $2.37, up 4.41% with a neutral technical signal despite bullish moving averages. The company shows mixed fundamentals with a high P/E ratio of 258.82 but improving cash flow trends, with Q2 2026 earnings beating expectations. Recent news highlights strategic integrations with AI-native ERP platforms and European expansion of its corporate card offering, signaling growth initiatives.
The outlook remains speculative with analyst consensus bullish (50% buy ratings) and a $13.75 price target, but negative net income margins and competitive pressures pose risks. Investment opportunity hinges on successful execution of AI-driven products and international growth, while downside risks include sustained profitability challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Expensify Inc
Expensify Inc is a cloud-based expense management software platform that helps the smallest to the largest businesses simplify the way they manage money. More than 10 million people use Expensify's free features, which include corporate cards, expense tracking, next-day reimbursement, invoicing, bill pay, and travel booking in one app.
Read more on EXFY →
